ProSTEM is led by a team of experts with a wealth of experience that focuses on the quality and services of stem cells, cells, and their metabolites and actively participates in national and international organizations, congresses, and seminars. ProSTEM also collaborates with governments and hospitals for stem cells, cells, and their metabolite development.
Andi Wijaya, Ph.D
Chairman
ProSTEM is initiated by Andi Wijaya, Ph.D., who also serves as the President Commissioner of PT. Prodia Widya Husada, Tbk. With a mission to advance regenerative medicine in Indonesia, he has established PT. Prodia StemCell Indonesia as an expansion of PT. Prodia Widyahusada, Tbk, which specializes in the storage, processing, research, and development in the field.
Andi Wijaya, Ph.D
Chairman
ProSTEM is initiated by Andi Wijaya, Ph.D., who also serves as the President Commissioner of PT. Prodia Widya Husada, Tbk. With a mission to advance regenerative medicine in Indonesia, he has established PT. Prodia StemCell Indonesia as an expansion of PT. Prodia Widyahusada, Tbk, which specializes in the storage, processing, research, and development in the field.
Andi Wijaya, Ph.D. is a scientist in clinical chemistry who has a fairly long academic profile in the history of his work. He has taught at various state universities in Indonesia. such as the Bandung Institute of Technology (ITB), Padjadjaran University (UNPAD), and has served as Head of the Postgraduate Clinical Chemistry/Biomedicine Study Program at Hassanuddin University.
Many achievements have been made in the fields of academic research and business. He received awards as a Fellow from the National Academy of Clinical Biochemistry (FACB), The National Academy of Atherosclerosis Thrombosis and Vascular Biology (FATVB), New York Academy of Science (FNAS), American Association for Clinical Chemistry (AACC), Clinical Laboratory Management Association (CLMA), Golden Academy Award from the National Academy of Clinical Biochemistry, Gold Record of Achievement in Science from NCCCA (USA), and Ganesa Widya Jasa Utama from ITB. He is also active as a member of stem cell associations such as the International Society for Stem Cell Research (ISSCR) and the International Society for Cell Therapy (ISCT).
Because of his extensive knowledge of stem cells and molecular biology, Andi Wijaya is often invited as a resource person or speaker at scientific seminars held in Indonesia. He has also been a promoter of several researchers conducting stem cell research since 2000 and is currently actively teaching at the postgraduate program at Hasanuddin University.
Dr. Cynthia R. Sartika, M.Si
Director
ProSTEM is led by Dr. Cynthia Retna Sartika, M.Si, who serves as the Director. She possesses a strong academic background in research. Her expertise in the field of research, particularly in stem cells, is unquestionable. She completed her bachelor's degree (S-1) in Biology at Universitas Padjajaran, then pursued her master's degree (S-2) in Biomedical Sciences with a concentration in Clinical Chemistry at Universitas Hasanuddin. She also obtained her doctoral degree (S-3) from the same university's Faculty of Medicine, graduating with honors (Cum Laude), and was recognized as the best PhD student of the 2006 cohort in the PhD program at Universitas Hasanuddin.
Dr. Cynthia R. Sartika, M.Si
Director
ProSTEM is led by Dr. Cynthia Retna Sartika, M.Si, who serves as the Director. She possesses a strong academic background in research. Her expertise in the field of research, particularly in stem cells, is unquestionable. She completed her bachelor's degree (S-1) in Biology at Universitas Padjajaran, then pursued her master's degree (S-2) in Biomedical Sciences with a concentration in Clinical Chemistry at Universitas Hasanuddin. She also obtained her doctoral degree (S-3) from the same university's Faculty of Medicine, graduating with honors (Cum Laude), and was recognized as the best PhD student of the 2006 cohort in the PhD program at Universitas Hasanuddin.
Her research is angiogenesis in obesity, where that condition is closely related to the development and continuation of stem cell quality. Her existence in scientific publications is proven by her latest publication in 2021 "Differentiation capacity of dental pulp stem cells into inner ear hair cells using an in vitro assay: a preliminary step toward treating sensorineural hearing loss. Eur Arch Otorhinolaryngol.”, “Case Report: Safety Profile of Allogeneic Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for adrenoleukodystrophy. Cytotherapy”, “Effect of Serum from Type 2 Diabetes Mellitus Patient in Mesenchymal Stemm Cell-derived Secretome in Total Protein. Cytotherapy”, “Standard Regulation for Stem Cell Products in Indonesia. Cytotherapy.”, and “Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. Regenerative Engineering and Translational Medicine.Her research is angiogenesis in obesity, where that condition is closely related to the development and continuation of stem cell quality. Her existence in scientific publications is proven by her latest publication in 2021 "Differentiation capacity of dental pulp stem cells into inner ear hair cells using an in vitro assay: a preliminary step toward treating sensorineural hearing loss. Eur Arch Otorhinolaryngol.”, “Case Report: Safety Profile of Allogeneic Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for adrenoleukodystrophy. Cytotherapy”, “Effect of Serum from Type 2 Diabetes Mellitus Patient in Mesenchymal Stemm Cell-derived Secretome in Total Protein. Cytotherapy”, “Standard Regulation for Stem Cell Products in Indonesia. Cytotherapy.”, and “Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. Regenerative Engineering and Translational Medicine.” Apart from actively participating in various congresses about stem cell research and therapeutic applications overseas, Cynthia R Sartika also often acts as a speaker at scientific seminars and provides suggestions/knowledge about stem cells in Indonesia. In 2020, she had the opportunity to be a speaker on "MSC-derived Extracellular Vesicles: The New Era of Regenerative Medicine at the Regenerative Medicine Series: The Current Overview for Research Translation in Clinical Application Using Mesenchymal Stem Cell and Condition Medium" and "Application of MSC for Next Level Therapy at the Thermoscientific Virtual Seminar", and in 2021 she was a speaker on "Current Perspective of MSC-EVs: Extended Messages of Regeneration at the 18th APASTB" and a speaker on "Strategies and Experiences in Preparing for Certification at CPOB Training for Vaccine Researchers and BPOM Stem Cells” She is also active in several organizations. In 2011, she was appointed by the Ministry of Health of the Republic of Indonesia to be one of the ad hoc teams in preparing standardization for stem cells processing and storage from umbilical cord blood. She is also active as a member of the International Society for Stem Cell Research (ISSCR), International Society for Cell Therapy (ISCT), Secretary General of the Indonesian Association of Atherosclerosis and Vascular Diseases (PAPVI), Member of the Cord Blood Association, Adhoc Team for Revision of Ministerial Regulations Health No. 48, 50 and 62 concerning Stem Cells and Tissues, General Secretary of the Stem Cell Development Consortium for 2 periods, in 2014-2019 and 2019-present periods, Deputy Chair of the Indonesian Stem Cell Association (ASPI) from 2019 until now. In 2021, she was entrusted to be a member and director of Commission III of the Stem Cell Development and Tissue Engineering Committee, created by the Indonesian Ministry of Health. Not only in Indonesia, she is also active in Asia organizations such as ACTO (Asian Cellular Therapy Organization)..”, “Case Report: Safety Profile of Allogeneic Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for adrenoleukodystrophy. Cytotherapy”, “Effect of Serum from Type 2 Diabetes Melitus Patient in Mesenchymal Stemm Cell-derived Secretome in Total Protein. Cytotherapy”, “Standard Regulation for Stem Cell Products in Indonesia. Cytotherapy.”, dan “Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. Regenerative Engineering and Translational Medicine.”
Apart from actively participating in various congresses about stem cell research and therapeutic applications overseas, Cynthia R Sartika also often acts as a speaker at scientific seminars and provides suggestions/knowledge about stem cells in Indonesia. In 2020, she had the opportunity to be a speaker on "MSC-derived Extracellular Vesicles: The New Era of Regenerative Medicine at the Regenerative Medicine Series: The Current Overview for Research Translation in Clinical Application Using Mesenchymal Stem Cell and Condition Medium" and "Application of MSC for Next Level Therapy at the Thermoscientific Virtual Seminar", and in 2021 she was a speaker on "Current Perspective of MSC-EVs: Extended Messages of Regeneration at the 18th APASTB" and a speaker on "Strategies and Experiences in Preparing for Certification at CPOB Training for Vaccine Researchers and BPOM Stem Cells”MSC-derived Extracellular Vesicles: The New Era of Regenerative Medicine pada Regenerative Medicine Series: The Current Overview for Research Translation in Clinical Application Using Mesenchymal Stem Cell and Conditione MediumandApplication of MSC for Next Level Therapy pada Thermoscientific Virtual Seminarin 2021 she was a speaker onCurrent Perspective of MSC-EVs: Extended Messages of Regeneration at the 18th APASTB and a speaker on "Strategies and Experiences in Preparing for Certification at CPOB Training for Vaccine Researchers and BPOM Stem Cells”
She is also active in several organizations. In 2011, she was appointed by the Ministry of Health of the Republic of Indonesia to be one of the ad hoc teams in preparing standardization for stem cells processing and storage from umbilical cord blood. She is also active as a member International Society for Stem Cell Research (ISSCR), International Society for Cell Therapy (ISCT), Secretary General of the Indonesian Association of Atherosclerosis and Vascular Diseases (PAPVI), Member of the Cord Blood Association, Adhoc Team for Revision of Ministerial Regulations Health No. 48, 50 and 62 concerning Stem Cells and Tissues, General Secretary of the Stem Cell Development Consortium for 2 periods, in 2014-2019 and 2019-present periods, Deputy Chair of the Indonesian Stem Cell Association (ASPI) from 2019 until now. In 2021, she was entrusted to be a member and director of Commission III of the Stem Cell Development and Tissue Engineering Committee, created by the Indonesian Ministry of Health. Not only in Indonesia, she is also active in Asia organizations such as ACTO (Asian Cellular Therapy Organization).
Prof. Dr. Aw Tar-Choon, MBBS, M.Med, MRCP, FRCPE, FRCPA, FAMS, MPP
Medical Advisory
Prof. Dr. Aw Tar-Choon is an expert in medicine and clinical chemistry. He completed his medical education at the University of Malaya Medical School, followed by master at Harvard-NUS focusing on public policy. He brought his great attention to the world of regenerative medicine to jointly build the ProSTEM laboratory to become a leading cell-based therapy development laboratory.
Prof. Dr. Aw Tar-Choon, MBBS, M.Med, MRCP, FRCPE, FRCPA, FAMS, MPP
Medical Advisory
Prof. Dr. Aw Tar-Choon is an expert in medicine and clinical chemistry. He completed his medical education at the University of Malaya Medical School, followed by master at Harvard-NUS focusing on public policy. He brought his great attention to the world of regenerative medicine to jointly build the ProSTEM laboratory to become a leading cell-based therapy development laboratory.
Currently, Aw Tar-Choon serves as Medical Director at ICON Central Laboratories, Inc. and specialist doctor at Raffles Hospital & Senior Consultant in Laboratory Medicine at Changi General Hospital Singapore. Apart from his busy schedule, Aw Tar-Choon is also active in teaching at various leading universities, such as Monash University School of Medicine and National University of Singapore (NUS) Medical School. Some of the professional qualifications he has achieved include Board Certification in Internal Medicine from NUS and The Royal College of Physicians (UK), Sub-speciality Board Certification in Chemical Pathology from the Royal College of Pathologists of Australasia, member of the Royal College of Physicians (Edinburgh, Ireland), and The Academy of Medicine Singapore, the Executive Board of several world scientific institutions such as the Singapore Association of Clinical Biochemists, the Singapore Society of Pathology, and The Endocrine & Metabolic Society of Singapore.
Aw Tar-Choon is active as a expert and speaker at various scientific events in more than 21 countries to talk about topics on clinical chemistry, endocrinology, health policy, regenerative medicine, tissue engineering, and stem cells. To date, he has written more than 300 abstracts and 117 professional articles, including 12 books/book chapters on clinical chemistry, endocrinology and health policy.
Dr. dr. Dewi Wulandari, Sp.PK(K), M.Sc.
Doctor in Charge
Dr. dr. Dewi Wulandari, Sp.PK, M.Sc is take in charge of quality laboratorium in ProSTEM. She completed her general practitioner & clinical pathology specialist at the Faculty of Medicine, University of Indonesia, followed by Master's degree at Vrije Universiteit Amsterdam, majoring in Oncology.
Dr. dr. Dewi Wulandari, Sp.PK(K), M.Sc.
Doctor in Charge
Dr. dr. Dewi Wulandari, Sp.PK, M.Sc is take in charge of quality laboratorium in ProSTEM. She completed her general practitioner & clinical pathology specialist at the Faculty of Medicine, University of Indonesia, followed by Master's degree at Vrije Universiteit Amsterdam, majoring in Oncology.
She has completed his Doctoral education at the University of Indonesia with Cum Laude honors in 2022. Currently, he serves as Medical Staff at Dr. RSUP. Cipto Mangunkusumo (RSCM), Jakarta, and also the person in charge of the Prodia Stemcell Indonesia Laboratory (ProSTEM).
Dr. Bayu Winata Putera, M.Kes
Operational Manager
Bayu Winata Putera acts as Laboratory Manager of ProSTEM, completed and got the pharmacist profession at Padjadjaran University, West Java. He completed his postgraduate (Master's) education at Hassanuddin University, focus on Biomedicine with Clinical Chemistry Concentration.
Dr. Bayu Winata Putera, M.Kes
Operational Manager
Bayu Winata Putera acts as Laboratory Manager of ProSTEM, completed and got the pharmacist profession at Padjadjaran University, West Java. He completed his postgraduate (Master's) education at Hassanuddin University, focus on Biomedicine with Clinical Chemistry Concentration.
The research he studied was the role of obestatin visfatin on pancreatic beta cell proliferation. The research was published in the Indonesian Biomedical Journal (IBJ). He took Doctoral education at the Faculty of Medicine, Hasanuddin University. His dissertation entitled "Stem Cell Dynamics in Stroke Patients who have undergone Intra Arterial Heparic Flushing" which reviewed Hematopoietic Stem Cells (HSC), Mesenchymal Stem Cells (MSC), Endothelial Progenitor Cells (EPC) and Very Small Embryonic Like Cells (VSEL).
The dissertation was entitled "Stem Cell Dynamics in Stroke Patients who have undergone Intra Arterial Heparic Flushing" which reviewed Hematopoietic Stem Cells (HSC), Mesenchymal Stem Cells (MSC), Endothelial Progenitor Cells (EPC) and Very Small Embryonic Like Cells ( VSEL).
